ライフサイエンスコーパス: effector phase

1 recipient" skin to induce GVH tissue damage (effector phase).

2 d apoptosis with or without MCP-1 during the effector phase.

3 e chemokine plays a distinct role during the effector phase.

4 ted T helper cell production of IL-17 in the effector phase.

5 that LCs act during the priming and not the effector phase.

6 of memory cell precursors at the peak of the effector phase.

7 minal immune complex/complement/FcR-mediated effector phase.

8 secondary tissue damage in situ in the late, effector phase.

9 e, but not if IP-10 was depleted only in the effector phase.

10 ough cycloheximide (CHX) still triggered the effector phase.

11 required CD8 T cells during the priming and effector phase.

12 H nucleoprotein in lung examined in the late/effector phase.

13 vents are critical for the regulation of the effector phase.

14 (+) T cells in the spleen and CNS during the effector phase.

15 ress allergic airway inflammation during the effector phase.

16 osteoclasts, and vascularization in the CIA effector phase.

17 g Ag presentation that persisted through the effector phase.

18 ected epithelial cells as targets during the effector phase.

19 , much less is known about what controls the effector phase.

20 sensitization, but is proallergic during the effector phase.

21 adaptive immune response and an inflammatory effector phase.

22 ed during both the initial sensitization and effector phase.

23 he function of immune T cells in vivo at the effector phase.

24 rs that likely drive the disease through its effector phases.

25 reatment occurred only during the challenge (effector) phase.

26 atory T (T(reg)) cells in the late infection/effector phase, 9 days post inoculation (p.i.), without

27 Late addition of Tregs into the effector phase abolished their ability to suppress effec

28 -molecule inhibitor during the tissue-damage effector phase abrogates the clinical manifestation of d

29 sion of CTLA4Ig and donor alloantigen in the effector phase (after cardiac engraftment) resulted in l

30 During the effector phase, all the LCMV-specific IFN-gamma(+) CD4 T

31 , immune regulatory pathways can subvert the effector phase and enable tumor escape.

32 in lymphoid tissues at the waning end of the effector phase and microbial clearance.

33 The multiple roles of Argonautes in the RNAi effector phase and miRNA biogenesis and maturation sugge

34 recognized to play an important role in the effector phase and propagation of the immune response in

35 ory CD8(+) T cells appear to pass through an effector phase and then gradually down-regulate expressi

36 ed for CD8(+) T cell cytotoxicity during the effector phase and tumor elimination.

37 ne responses during both the priming and the effector phases and provides a strategy to overcome T(re

38 high affinity in the tumor microenvironment (effector phase) and the TDLNs (cognitive phase) signific

39 stinct clinical scores and pathology (onset, effector phase, and peak of EAN severity), intravenously

40 adaptive cellular subsets in the activation, effector phases, and target organ specificity of acute G

41 The effector phases are conveniently modeled by the K/BxN se

42 e timing of AICD, and thus the length of the effector phase, are regulated by transient expression of

43 aradigm defines a late checkpoint during the effector phase at which cognate interactions direct CD4

44 In contrast, IFN-gamma treatment during the effector phase attenuated disease.

45 with anti-PD-L1 antibody present during the effector phase but not during the priming culture.

46 ere established initially during the primary effector phase but were maintained for weeks, into the m

47 en (Ag) presentation lasting through the CD4 effector phase, but Ag and pathogen recognition receptor

48 lly in the site of T(FH) development, at the effector phase, but did not depend on specific Ag-presen

49 sis of murine allergic conjunctivitis at the effector phase, but not during the initial sensitization

50 at complement plays an essential role in the effector phase, but not the inductive phase, of RRV-indu

51 in antibiotic-pretreated mice undergo brief effector phase, but rapidly develop phenotypic (CD127(hi

52 n, though a role for this interaction in the effector phase cannot be ruled out.

53 ue damage when added to the skin co-culture (effector phase), concurrently with primed T cells.

54 ic CD8(+) T cells passed through an obligate effector phase, contracted more than 90% and gradually d

55 express surface activation markers, contain effector phase cytokine mRNAs, and contain perforin and

56 ne initiation (early blockade) or the immune effector phase (delayed blockade).

57 Induction-phase and effector-phase depletions of T cell subsets were perform

58 nd these changes are already manifest in the effector phase despite the presence of Ag-expressing den

59 of live attenuated influenza vaccine at the effector phase drove T(FH) and GC-T(FH) development equi

60 TGF-beta at several different (including the effector) phases during the response.

61 fic monoclonal antibody (mAb) CC1 during the effector phase exhibited a reduced severity of trinitrob

62 +) T cells adoptively transferred during the effector phase fail to expand without DC, CD28 costimula

63 flammatory cytokines, results in a transient effector phase followed by the accelerated acquisition o

64 cells on the same dendritic cell during the effector phase, forming a three-cell-type cluster (triad

65 or-infiltrating lymphocytes are defective in effector phase function, demonstrating tumor-induced imm

66 ck) activation motif (Y394), thus inhibiting effector phase functions.

67 ring mice are deficient in either priming or effector phase functions.

68 At the effector phase, IFN-gamma production by transferred T ce

69 hat IL-2 plays a central role throughout the effector phase in regulating the balance between Th1 and

70 ing for self-antigen-specific T cells at the effector phase in target tissues.

71 r to the onset of the disease and during the effector phase in the ovalbumin-induced allergic airway

72 ring the induction phase but also during the effector phase in the tumor microenvironment, implying a

73 that CD4 T cells from the early stage of the effector phase in which both the Ag and activation are o

74 e response was characterized by a protracted effector phase in which cytolytic activity in the lamina

75 More diverse elements are required for the effector phase, including components from the innate imm

76 demonstrated that blocking IL-10 during the effector phase increased not only the incidence and seve

77 d alpha2 were found to significantly inhibit effector phase inflammatory responses in animal models o

78 ersistence of viral Ag presentation into the effector phase is the key factor that determines the eff

79 In the effector phase, loss of CTLA-4 on Tfh cells resulted in

80 hich demonstrates an impact of Treg cells on effector phase manifestations.

81 vade host immunity at both the induction and effector phases Most studies have focused on tumor evasi

82 he contribution of mucosal mast cells to the effector phase of a secondary immune response to Trichin

83 disease (GVHD), but the role of APCs in the effector phase of acute GVHD is not known.

84 tes derived from spleens of males during the effector phase of adoptive EAE produced significantly hi

85 e data identify a novel role for CD28 in the effector phase of allergic airway inflammation and sugge

86 To study the role of CD28 in the effector phase of allergic airway inflammation, we devel

87 as a critical role in both the induction and effector phase of allergic airway inflammation.

88 sponsiveness and mucus production during the effector phase of allergic asthma.

89 een IL-4 and vasoactive mediators during the effector phase of allergic inflammation may both contrib

90 eating the critical immune components of the effector phase of allergic reactions to food.

91 as essential for germinal centers and in the effector phase of allergic responses.

92 as essential for germinal centers and in the effector phase of allergic responses.

93 allergic responses, also contributes to the effector phase of allergy.

94 y inhibiting the innate immune cell-mediated effector phase of alloimmunity.

95 umor microenvironment dominantly resists the effector phase of an anti-tumor T cell response, contrib

96 regulatory role for epidermal LCs during the effector phase of an inflammatory immune response in the

97 served and divergent components of the rapid effector phase of antigen-specific IgM(+) versus inflamm

98 on of tumor cells, at both the induction and effector phase of antitumor immunity.

99 During the effector phase of apoptosis, caspase activation appears

100 endent and occurs prior to commitment to the effector phase of apoptosis, definitively ordering ceram

101 rocaspase-8 processing and activation of the effector phase of apoptosis.

102 ysteine proteases play a pivotal role in the effector phase of apoptosis.

103 te essential homeostatic pathways during the effector phase of apoptosis.

104 T and B lymphocyte-independent model of the effector phase of arthritis and is induced by well-defin

105 hat Bim potentially functions to repress the effector phase of arthritis by regulating the milieu of

106 esults argues that our focus on the terminal effector phase of arthritis in the K/BxN model will bear

107 mic delivery of poly(IC) on the inflammatory effector phase of arthritis using the collagen Ab-induce

108 sis of chemokines and their receptors in the effector phase of arthritis using the K/BxN mouse serum-

109 transfer, thereby focussing on the end-stage effector phase of arthritis, leap-frogging the initiatin

110 II expression appears to be important in the effector phase of arthritis, possibly by activating cyto

111 n addition, ICAM-1 also played a role in the effector phase of autoimmune diabetes because adoptive t

112 effective in preventing the insulitis or the effector phase of autoimmune diabetes.

113 and have implications for regulation of the effector phase of CD8+ T cell responses in tissue microe

114 is impacted by prolonged stimulation during effector phase of chronic infection, we adoptively trans

115 e inhibitory receptor PD-1 occurs during the effector phase of chronic viral infection.

116 that regulate inflammatory responses in the effector phase of CHS, we performed further investigatio

117 nd inflammatory KC hyperproliferation in the effector phase of CHS.

118 egulate T cell-dependent inflammation in the effector phase of CHS.

119 s in the initial stage and IgG2a Ab's at the effector phase of collagen-induced arthritis.

120 ratumoral myeloid cells did not suppress the effector phase of CTL.

121 In addition to caspase 3-like proteases, the effector phase of death involves the activation in the n

122 ssed by substantially fewer cells during the effector phase of disease and peaked during remission, w

123 CD8(+) T cell depletion in the effector phase of disease attenuated injury in murine an

124 nimize their suppressive activity during the effector phase of disease control.

125 al by CD40L is required early but not in the effector phase of disease development.

126 vity, we examined the effect of IL-27 at the effector phase of disease using adoptive transfer EAE.

127 that the blockade of cPLA(2)alpha during the effector phase of disease was more efficacious in amelio

128 to allow for study of the induction and the effector phase of disease, the adoptive EAE model was ch

129 stive of a harmful role of complement in the effector phase of disease.

130 intrathecal delivery of TGF-beta2 during the effector phase of EAE ameliorated disease severity.

131 r-deficient mice, IFN-gamma treatment during effector phase of EAE exacerbated disease.

132 ameliorating disease pathogenesis during the effector phase of EAE in the adoptive transfer model of

133 IL-27 can potently suppress the effector phase of EAE in vivo and, thus, may have therap

134 r, whether IL-27 influences the induction or effector phase of EAE is unknown.

135 t compensate for IL-23 deficiency during the effector phase of EAE.

136 ndicates that cPLA2alpha plays a role in the effector phase of EAE.

137 t-mediated events may occur early during the effector phase of EAE.

138 st that costimulation is required during the effector phase of EAT and that B7.2 may have opposing ro

139 ession associated with the sensitization and effector phase of EAU pathogenesis.

140 urine type VII collagen into mice mimics the effector phase of EBA and results in a subepidermal blis

141 e contribution of GM-CSF specifically in the effector phase of EBA, disease was induced by transfer o

142 the functional relevance of C5aR2 during the effector phase of EBA.

143 ion of MOG-reactive T cells, but also in the effector phase of encephalitogenic T cell activation wit

144 mulatory molecules that are important in the effector phase of experimental autoimmune uveitis (EAU).

145 intestinal inflammation and induction of the effector phase of food allergy.

146 e mechanism underlying the sensitization and effector phase of food allergy.

147 g NTN, CCR1 expression profoundly alters the effector phase of glomerulonephritis.

148 nner suggesting a role for glycolipid in the effector phase of IgE-mediated food allergy.

149 milieu within the tumor lesion to boost the effector phase of immune responses in enhancing the anti

150 Oral antigen re-encounter during the effector phase of immune responses potentiated TRM estab

151 une responses are interesting models for the effector phase of immunity, in that granulomas can be pa

152 ss-presentation of tumor antigens during the effector phase of immunotherapy and suggest that approac

153 lations of memory precursor cells during the effector phase of infection and memory CD4(+) T cells fo

154 stimulatory CpG-ODNs strongly inhibited the effector phase of inflammatory arthritis in the K/BxN se

155 K/BxN serum-transfer system, focused on the effector phase of inflammatory arthritis.

156 ghting a new aspect of complement during the effector phase of inflammatory arthritis.

157 rs and it can be manipulated to activate the effector phase of innate immune responses.

158 igands (polyI:C/CpG) into a tumor during the effector phase of lentivector (lv) immunization effectiv

159 ts from experimental studies relating to the effector phase of Lewis rat EAN that may be relevant to

160 hich kinase inhibitors were added during the effector phase of lysis indicated that protein-tyrosine

161 ing a role for an NHL-2:CGH-1 complex in the effector phase of miRISC activity.

162 The effector phase of morphine-induced apoptosis appears to

163 nstrate a role for IL-12 and NK cells in the effector phase of murine SGVHD.

164 B:9-23 for both the initial priming and the effector phase of NOD anti-islet autoimmunity.

165 dendritic cells (DCs) may be involved in the effector phase of peanut-induced intestinal anaphylaxis.

166 To determine whether the effector phase of protection in vivo to the rodent paras

167 r mast cells in the mechanism underlying the effector phase of protective immunity against T. spirali

168 r capacity to recruit T cells to amplify the effector phase of pulmonary inflammation.

169 l mice, but was not sufficient to induce the effector phase of pulmonary inflammation.

170 of M effector functions that facilitate the effector phase of pulmonary inflammation.

171 or the proapoptotic Bcl-2 protein Bim in the effector phase of RA.

172 e mechanisms assume an important role in the effector phase of rejection once these cell-cytotoxic pa

173 NF-alpha is in wound-healing rather than the effector phase of rejection.

174 cells native to the lung contributes to the effector phase of some allergic responses.

175 ts from chronic stimulation that extends the effector phase of T cell activation, at the expense of T

176 ss-presented peptides can participate in the effector phase of T cell-mediated inflammatory responses

177 This helper role occurs during the effector phase of the anti-tumor immune response and is

178 ld be exploited to overcome obstacles at the effector phase of the antitumor immune response and impr

179 ole for chemokines in the development of the effector phase of the antitumor immune response has been

180 acts at the level of priming rather than the effector phase of the antitumor immune response.

181 The importance of CD4+ Th1 cells during the effector phase of the antitumor response has been oversh

182 le for this inflammatory mediator during the effector phase of the autoimmune process.

183 B7-2 does not impact the effector phase of the autoimmune response as adoptive tr

184 r DCs, Ag, and CD28 costimulation during the effector phase of the CD8(+) T cell response.

185 in additional aspects of ACD, including the effector phase of the classic type IV hypersensitivity r

186 of IL-4 and IL-10, which interfere with the effector phase of the diabetic process.

187 f K/BxN T cell receptor transgenic mice, the effector phase of the disease is provoked by binding of

188 To study the role of B7 molecules in the effector phase of the disease, MOG 35-55-specific T line

189 n situ CD4(+) T cell accumulation during the effector phase of the disease.

190 litogenic responses during the tissue damage effector phase of the disease.

191 diation-resistant stromal cells promoted the effector phase of the disease.

192 g that loss of VIP specifically affected the effector phase of the disease.

193 r"-derived Treg were added at the priming or effector phase of the GVH response.

194 del of myasthenia gravis (PTMG) reflects the effector phase of the human condition and is induced in

195 ning lymph nodes rather than suppressing the effector phase of the immune response in the periphery.

196 Treg can suppress antitumor immunity at the effector phase of the immune response induced by adoptiv

197 required only for tumor cell killing in the effector phase of the immune response.

198 suggesting a role for CD8(+) T cells in the effector phase of the immune response.

199 hages substantially outnumber AMs during the effector phase of the immune response; and accumulation

200 ope on virus-specific CD8 T cells during the effector phase of the primary cytotoxic T lymphocyte (CT

201 n skin allograft microvasculature during the effector phase of the rejection response.

202 serves as an inhibitory mechanism during the effector phase of the response.

203 required for the induction, maintenance, and effector phase of the Th1 response after LACK DNA vaccin

204 ather, CD4(+) T cells appeared to act at the effector phase of tumor rejection and responded to B16-d

205 ated a requirement for CD4(+) T cells in the effector phase of tumor rejection indicating a greater r

206 However, analysis of the effector phase of tumor rejection induced by vaccination

207 sms by which anti-LFA-1alpha Ab inhibits the effector phase of uveitis demonstrated that it blocks mu

208 elevant participants in both the priming and effector phases of acute graft rejection.

209 ells was determined in the sensitization and effector phases of allergic airway inflammation in mice.

210 regulatory function in the sensitization and effector phases of allergic asthma and to determine the

211 role at many levels of the sensitization and effector phases of allograft rejection.

212 ementary effects of radiation on priming and effector phases of antitumor immunity make it an appeali

213 7 and CTLA4-B7 interactions in induction and effector phases of antitumor immunity.

214 roles in stimulating both the initiation and effector phases of autoimmunity and that CD28 regulates

215 olvement of CMKLR1 in both the induction and effector phases of disease.

216 ce of B7 costimulators for the induction and effector phases of experimental autoimmune encephalomyel

217 ble mechanistic studies on sensitization and effector phases of humoral alloreactivity as well as eff

218 apeutic target that links the initiation and effector phases of humoral autoimmune disease.

219 e cytokines influence both the formative and effector phases of insulitis, it is critical to determin

220 Multiple pathways in both the priming and effector phases of melanoma rejection have been describe

221 nst paralysis, during both the induction and effector phases of relapsing experimental autoimmune enc

222 subunits and its receptor in the CNS at the effector phases of relapsing-remitting EAE including dis

223 cells are responsible for the induction and effector phases of SGVHD, the role of nonspecific effect

224 resenting cells (APC) during the priming and effector phases of T cells' function, and during natural

225 vely up-regulated during differentiation and effector phases of Th subsets.

226 oles for BRP-39/YKL-40 in the initiation and effector phases of Th2 inflammation and remodeling and s

227 ed to play key roles in both the priming and effector phases of the antitumor immune response.

228 Thus, NK cells operate in both induction and effector phases of the disease.

229 multisite manipulation of the initiation and effector phases of the IL-17 inflammatory network.

230 NA) pathway components in the initiation and effector phases of transposon silencing.

231 phils play a key role in the development and effector phases of type 2 immune responses in both aller

232 play an important role in the induction and effector phases of type 2 immune responses.

233 tical role in the induction, rather than the effector, phase of the disease.

234 activated T cells, extended a duration of an effector-phase of a specific immune response, and increa

235 uired at the inductive phase, but not at the effector phase, of the Th1 response within the infected

236 g resveratrol during either the induction or effector phase or through the whole course of EAE.

237 mmunosuppression during both the priming and effector phases, provokes systemic T cell responses agai

238 h antigen and costimulatory molecules at the effector phase raised an interesting question on the nat

239 progression, and their depletion during the effector phase, rather than priming phase, successfully

240 +) T cells expanding in the lungs during the effector phase require Ag, CD28 costimulation, and DCs f

241 es, respectively, but a role for Dectin-2 in effector phase responses has not been described.

242 llergen sensitisation, but restricts the Th2 effector phase responsible for inflammation.

243 nses akin to infection, if they supply these effector phase signals at the right time and site.

244 host stromal cells, where it can inhibit the effector phase the immune response.

245 -MHC class II epitopes to link inductive and effector phases to generate protective immunity.

246 P2RX7-high expression is confined, at peak effector phase, to CD62L(+) memory precursors, which pre

247 or both infection and Ag presentation at the effector phase, using an in vivo sequential transfer mod

248 2) This effector phase was characterized by down-regulation of C

249 cted sensitized mice, demonstrating that the effector phase was targeted.

250 SF blockade were linked to modulation of the effector phase, whereas effects on early pathogenic even